SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-22-008239
Filing Date
2022-05-11
Accepted
2022-05-11 08:30:35
Documents
60
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q blph-20220331x10q.htm   iXBRL 10-Q 861809
2 EX-31.1 blph-20220331xex31d1.htm EX-31.1 9845
3 EX-31.2 blph-20220331xex31d2.htm EX-31.2 9380
4 EX-32 blph-20220331xex32.htm EX-32 9136
  Complete submission text file 0001558370-22-008239.txt   4296310

Data Files

Seq Description Document Type Size
5 EX-101.SCH blph-20220331.xsd EX-101.SCH 37419
6 EX-101.CAL blph-20220331_cal.xml EX-101.CAL 26868
7 EX-101.DEF blph-20220331_def.xml EX-101.DEF 134551
8 EX-101.LAB blph-20220331_lab.xml EX-101.LAB 318822
9 EX-101.PRE blph-20220331_pre.xml EX-101.PRE 257312
54 EXTRACTED XBRL INSTANCE DOCUMENT blph-20220331x10q_htm.xml XML 691737
Mailing Address 184 LIBERTY CORNER ROAD, SUITE 302 WARREN NJ 07059
Business Address 184 LIBERTY CORNER ROAD, SUITE 302 WARREN NJ 07059 908-574-4770
Bellerophon Therapeutics, Inc. (Filer) CIK: 0001600132 (see all company filings)

IRS No.: 473116175 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36845 | Film No.: 22912179
SIC: 2834 Pharmaceutical Preparations